Treatment Outcomes and Quality-of-Life Issues for Patients Treated With Prostate Brachytherapy

Laurie Abel, RN, BSN, OCN®, Jane Dafoe-Lambie, RN, BSN, OCN®, Wayne M. Butler, PhD, and Gregory S. Merrick, MD

The increasing popularity of brachytherapy for treatment of early-stage prostate cancer requires oncology nurses to have a comprehensive knowledge of the disease, its treatment, and management of side effects. Because quality-of-life (QOL) issues have become an important consideration in treatment selection for many patients, oncology nurses must have a thorough understanding of these QOL issues and their management. Armed with knowledge about prostate brachytherapy and its effect on QOL, oncology nurses can offer accurate information and evidence-based symptom management techniques to patients undergoing brachytherapy for prostate cancer.

Key Words: prostatic neoplasms, radioisotope brachytherapy, quality of life

Risk Stratification

No prospective randomized trials have offered a comparative analysis of the efficacy of treatment options. Therefore, risk stratification based on pretreatment PSA, clinical staging, and the Gleason score has been invaluable in comparing treatment outcomes.

PSA is a protein produced by the lining of the prostate. In normal, healthy men, a small amount of this protein (0–4 ng/ml) can be detected in the bloodstream. In men with prostate cancer, a larger amount is produced. PSA also can be abnormally elevated in men with benign prostatic hypertrophy. However, in men diagnosed with prostate adenocarcinoma, the higher the pretreatment PSA (i.e., PSA level at the time of biopsy), the more aggressive the disease. This univ- erse knowledge about prostate brachytherapy and its effect on QOL, oncology nurses can offer accurate information and evidence-based symptom management techniques to patients undergoing brachytherapy for prostate cancer.

Key Words: prostatic neoplasms, radioisotope brachytherapy, quality of life

Risk Stratification

No prospective randomized trials have offered a comparative analysis of the efficacy of treatment options. Therefore, risk stratification based on pretreatment PSA, clinical staging, and the Gleason score has been invaluable in comparing treatment outcomes.

PSA is a protein produced by the lining of the prostate. In normal, healthy men, a small amount of this protein (0–4 ng/ml) can be detected in the bloodstream. In men with prostate cancer, a larger amount is produced. PSA also can be abnormally elevated in men with benign prostatic hypertrophy. However, in men diagnosed with prostate adenocarcinoma, the higher the pretreatment PSA (i.e., PSA level at the time of biopsy), the more aggressive the disease. This universally recognized scoring system is reliable, reproducible, time efficient, and of significant

Submitted May 2002. Accepted for publication June 18, 2002. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/03.CJON.48-54